The Bull Case For Exact Sciences (EXAS) Could Change Following Walgreens’ Nationwide Cologuard Pharmacy Rollout

Simply Wall St.03-22

In March 2026, Walgreens announced a nationwide initiative with Exact Sciences and Workflow Services that lets eligible, average-risk customers request the FDA-approved, at-home Cologuard colorectal ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2621791826?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","is_english":true,"pubTime":"2026-03-22 03:13","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2621791826","market":"nz","top_or_hot":-1,"title":"The Bull Case For Exact Sciences (EXAS) Could Change Following Walgreens’ Nationwide Cologuard Pharmacy Rollout","media":"Simply Wall St.","content":"<div>\n<p>In March 2026, Walgreens announced a nationwide initiative with Exact Sciences and Workflow Services that lets eligible, average-risk customers request the FDA-approved, at-home Cologuard colorectal ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-exas/exact-sciences/news/the-bull-case-for-exact-sciences-exas-could-change-following\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>The Bull Case For Exact Sciences (EXAS) Could Change Following Walgreens’ Nationwide Cologuard Pharmacy Rollout</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nThe Bull Case For Exact Sciences (EXAS) Could Change Following Walgreens’ Nationwide Cologuard Pharmacy Rollout\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-03-22 03:13 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-exas/exact-sciences/news/the-bull-case-for-exact-sciences-exas-could-change-following><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>In March 2026, Walgreens announced a nationwide initiative with Exact Sciences and Workflow Services that lets eligible, average-risk customers request the FDA-approved, at-home Cologuard colorectal ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-exas/exact-sciences/news/the-bull-case-for-exact-sciences-exas-could-change-following\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU0266013472.USD","symbol_name":"AXA WF - Framlington Longevity Economy A Cap USD","start_time":0,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-exas/exact-sciences/news/the-bull-case-for-exact-sciences-exas-could-change-following","article_id":"2621791826","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-exas/exact-sciences/news/the-bull-case-for-exact-sciences-exas-could-change-following","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2621791826","pubTimestamp":1774120421,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"In March 2026, Walgreens announced a nationwide initiative with Exact Sciences and Workflow Services that lets eligible, average-risk customers request the FDA-approved, at-home Cologuard colorectal cancer screening test through its pharmacies, aiming to close care gaps with pharmacist-led services integrated into store workflows.\nAt the same time, Exact Sciences highlighted new data on its Oncodetect molecular residual disease test and Cancerguard multi-cancer early detection assay at the...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU0266013472.USD":"AXA WF - Framlington Longevity Economy A Cap USD","BK4588":"碎股","LU1861559042.SGD":"日兴方舟颠覆性创新基金B SGD","LU1861558580.USD":"日兴方舟颠覆性创新基金B","BK4585":"ETF&股票定投概念","EXAS":"精密科学","BK4548":"巴美列捷福持仓","LU2324357040.USD":"HSBC GIF GLOBAL EQUITY SUSTAINABLE HEALTHCARE \"AC\" (USD) ACC","BK4139":"生物科技"},"translate_title":"沃尔格林在全国范围内推出Cologuard药房后，Exact Sciences(EXAS)的牛市可能会发生变化","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"EXAS":1.5},"content_text":"In March 2026, Walgreens announced a nationwide initiative with Exact Sciences and Workflow Services that lets eligible, average-risk customers request the FDA-approved, at-home Cologuard colorectal cancer screening test through its pharmacies, aiming to close care gaps with pharmacist-led services integrated into store workflows. At the same time, Exact Sciences highlighted new data on its Oncodetect molecular residual disease test and Cancerguard multi-cancer early detection assay at the 2026 AACR Annual Meeting, underscoring how its tools may broaden cancer screening and monitoring options across different tumor types. We’ll now examine how Walgreens’ expanded Cologuard access through pharmacies could influence Exact Sciences’ investment narrative and long-term growth profile. Invest in the nuclear renaissance through our list of 89 elite nuclear energy infrastructure plays powering the global AI revolution.AdvertisementExact Sciences Investment Narrative RecapTo own Exact Sciences, you need to believe its cancer testing portfolio can eventually support consistent profits despite a history of cash burn and concentration in Cologuard. The Walgreens rollout of Cologuard access touches the key near term catalyst of expanding screening volumes, but does not remove the biggest risk that high R&D and M&A spending may continue to generate weak returns and keep margins under pressure. The Walgreens partnership stands out because it directly addresses care gaps in colorectal cancer screening, putting Cologuard in front of more eligible adults through pharmacy workflows. This ties into the broader catalyst of leveraging large distribution partners to widen access, while the new AACR data on Oncodetect and Cancerguard reinforces that Exact is also trying to diversify beyond its core stool based test. Yet beneath the Walgreens upside, investors should still be aware that... Read the full narrative on Exact Sciences (it's free!)Exact Sciences' narrative projects $4.1 billion revenue and $277.2 million earnings by 2028.Uncover how Exact Sciences' forecasts yield a $105.81 fair value, in line with its current price.Exploring Other PerspectivesEXAS 1-Year Stock Price Chart Before this Walgreens news, the most optimistic analysts were already assuming revenue could reach about US$4.4 billion and earnings US$677.9 million by 2028, so if you see faster pharmacy driven Cologuard uptake as validating that view, remember other investors worry that overdependence on Cologuard and rising competition could tell a very different story.Explore 5 other fair value estimates on Exact Sciences - why the stock might be worth as much as 44% more than the current price!The Verdict Is YoursDisagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.A great starting point for your Exact Sciences research is our analysis highlighting 4 key rewards that could impact your investment decision.Our free Exact Sciences research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Exact Sciences' overall financial health at a glance.Seeking Other Investments?Opportunities like this don't last. These are today's most promising picks. Check them out now:This technology could replace computers: discover 24 stocks that are working to make quantum computing a reality.Uncover the next big thing with 33 elite penny stocks that balance risk and reward.Capitalize on the AI infrastructure supercycle with our selection of the 35 best 'picks and shovels' of the AI gold rush converting record-breaking demand into massive cash flow.  This article by Simply Wall St is general in nature. We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.Valuation is complex, but we're here to simplify it.Discover if Exact Sciences might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.Access Free AnalysisHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.38.0","shortVersion":"4.38.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2621791826","isCrawlerRequest":true}